IRF9 Antibody
IRF9 is a transcription regulatory factor that mediates signaling by type I IFNs (IFN-alpha and IFN-beta) . Following type I IFN binding to cell surface receptors, Jak kinases (TYK2 and JAK1) are activated, leading to tyrosine phosphorylation of STAT1 and STAT2. The phosphorylated STATs dimerize, associate with IRF9/ISGF3G to form a complex termed ISGF3 transcription factor, that enters the nucleus. ISGF3 binds to the IFN stimulated response element (ISRE) to activate the transcription of interferon stimulated genes, which drive the cell in an antiviral state.
Product Specifications
CAS Number
9007-83-4
Specifications
Western blot: 1:1000, IHC (Paraffin) : 1:10-1:50, Immunofluorescence: 1:10-1:50
UniProt
Q00978
Host
Rabbit
Reactivity
Human, Mouse
Immunogen
A portion of amino acids 75-104 from the human protein was used as the immunogen for this IRF9 antibody.
Clonality
Polyclonal
Isotype
Ig
Applications
WB, IHC, IF, ELISA
Purity
Antigen affinity
Format
Antigen affinity purified
Buffer
In 1X PBS, pH 7.4, with 0.09% sodium azide
Reconstitution
Aliquot the IRF9 antibody and store frozen at -20oC or colder. Avoid repeated freeze-thaw cycles.
Limitations
This IRF9 antibody is available for research use only.
Storage Conditions
Aliquot the IRF9 antibody and store frozen at -20°C or colder. Avoid repeated freeze-thaw cycles.
Formulation
In 1X PBS, pH 7.4, with 0.09% sodium azide
Applications Notes
Titration of the IRF9 antibody may be required due to differences in protocols and secondary/substrate sensitivity.
Image Legend
Documents
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
CACNB2 (Voltage-dependent L-type Calcium Channel Subunit beta-2, CAB2, Calcium Channel Voltage-dependent Subunit beta 2, Lambert-Eaton Myasthenic Syndrome Antigen B, MYSB, CACNLB2, MYSB) (MaxLight 550)
APCS (Serum Amyloid P-component, SAP, 9.5S alpha-1-glycoprotein, PTX2) (MaxLight 650)
